Rapid Micro Biosystems to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rapid Micro Biosystems to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn. LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference.
馬薩諸塞州列剋星敦，2025年1月7日（全球新聞稿）——快速微生物系統公司（納斯達克：RPID）（"公司"）是一家創新的生命科學科技公司，爲高效製造和快速、安全釋放醫療產品提供重要的自動化解決方案，今天宣佈公司將在第43屆J.P.摩根醫療保健會議上進行展示。
The Company is scheduled to present on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at and can be accessed here. The webcast will be archived and available for replay after the event.
公司計劃於2025年1月16日週四下午12:45（東部時間）進行展示（太平洋時間上午9:45）。展示的現場直播網絡廣播將在快速微生物系統的投資者關係網站上提供，您可以在這裏訪問。網絡廣播將在活動後進行存檔並可供重播。
About Rapid Micro Biosystems
關於快速微生物系統
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
快速微生物系統是一家創新的生命科學科技公司，提供重要的自動化解決方案以促進醫療產品的高效製造及快速、安全的釋放，如生物製品、疫苗、電芯和基因治療以及無菌注射劑。公司的旗艦產品增長直系統，自動化和現代化了在全球最大和最複雜的藥品製造操作中使用的過時手動微生物質量控制（"MQC"）測試工作流程。增長直系統將質量控制實驗室帶到製造車間，解鎖MQC自動化的力量，提供客戶依賴的更快的結果、更高的準確性、增加的操作效率、更好的數據完整性合規性，以及更快的決策，以確保安全和一致的重要醫療產品供應。公司總部位於馬薩諸塞州列剋星敦，在馬薩諸塞州洛威爾設有美國製造工廠，並在瑞士、德國和荷蘭設有全球辦事處。有關更多信息，請訪問或在X（前稱Twitter）上關注公司@rapidmicrobio或在LinkedIn上關注。
CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
聯繫方式：投資者聯繫方式：
邁克爾·博利厄，CFA
投資者關係和公司通訊副總裁
mbeaulieu@rapidmicrobio.com
媒體聯繫人：
media@rapidmicrobio.com
譯文內容由第三人軟體翻譯。
